Bryan Johnson

Bryan Johnson has a highly public, durable, and ambitious future vision centered on defeating death and popularizing longevity through Blueprint and the Don't Die movement. The vision is clear and consistently messaged, with some concrete deployment pathways such as a longevity prescription platform, but the evidence provided is lighter on detailed scientific roadmap, timelines, risk handling, or directly endorsed mechanistic theories, which keeps it below field-defining maximum strength.

Bryan Johnson has some direct scientific authorship evidence in cancer biology papers related to senescence and melanoma mechanisms, but the strongest citation-metrics block appears mismatched to another researcher and high-energy-physics work, so it cannot credibly support a high scientific-impact score for him. The remaining evidence supports limited direct scientific contribution rather than field-defining impact.

The dimension applies because Bryan Johnson is presented as an entrepreneur/investor and longevity public figure, but the provided evidence contains no high- or medium-confidence disclosed investments, donations, or amounts deployed toward longevity. The strongest signals are institution-building claims around Blueprint/Don't Die and a self-published launch of a longevity prescription platform, which suggest some operational commitment but do not establish scale of capital deployed.

The evidence shows a coherent and high-risk strategy around translating Johnson's personal longevity protocol into consumer-facing products, medical access, partnerships, and media narrative. However, the record here is mostly self-published, very recent, and thin on early timing, counterfactual importance, field-level impact, or evidence that these choices opened paths others were not seeing.

The dimension applies, but the provided evidence only weakly supports field creation. The structured facts say Bryan Johnson founded one company, Minicircle, but it is listed as inactive and there is no supplied primary or independent corroboration showing that it created a durable organization, protocol, community, category, or funding path that made longevity work more possible for others.

The evidence supports a moderate bravery/conviction score primarily through public self-experimentation and visibility: Johnson publicly ties a longevity prescription platform to medications he says he personally uses, and presents a broad anti-death/longevity stance publicly. However, the supplied evidence does not substantiate stronger forms such as major career sacrifice, large relative financial risk, sustained conviction under serious criticism, or a clearly documented contrarian stand against mainstream opposition.

The dimension applies: the evidence suggests Johnson is trying to create second-order leverage through a longevity Rx platform, health-product partnerships, and media/cultural distribution. However, the concrete multiplier achievements are supported almost entirely by self-published X posts, with little independent or primary corroboration of actual talent attraction, capital mobilization, policy attention, durable collaborators, or follow-on projects. Under the independence gate, this cannot justify a score above 5.